Cost-effectiveness of using prothrombin complex concentrate to prevent complications related to overdoses of anticoagulants in the emergency department;Estudio de coste-efectividad del empleo de concentrado de complejo protrombínico en urgencias para evitar las complicaciones de la sobredosificación de anticoagulantes

Emergencias

Volumn 24, Issue 2, 2012, Pages 113-120

  Quintana Díaz, Manuel ^a   Borobia, Alberto M ^a   Pérez Cachafeiro, Santiago ^b   Rodríguez, Cilia ^c   García Erce, José Antonio ^d  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b I+D+i Complejo Hospitalario de Pontevedra ^*  (Spain)

^c Grupo de Investigación USEES URG   (Spain)

^d HOSPITAL SAN JORGE   (Spain)

Author keywords

Anticoagulants; Overdose; Prothrombin complex

Indexed keywords

EID: 84859149132     PISSN: 11376821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Haemost. 2007;98:790-7.
2. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet. 2007;370:439-48.
3. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:160S-98S.
5. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin). Br J Haematol. 2006;132:277-85.
6. Lorenz R, Kienast J, Otto U, Egger K, Kiehl M, Schreiter D, et al. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol. 2003;15:15-20.
7. Coagulation Management in Trauma Related Massive Bleeding. (Consultado 6 Septiembre 2011). Disponible en: http://www.oegari. at/arbeitsgruppe.asp?id=116
8. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11:R17.
9. World Federation of Haemophilia Registry of Clotting Factor Concentrates. (Consultado 5 Septiembre 2011). Disponible en: http://www.wfh.org/2/docs/Publications/Treatment_Products/Monographs/ FF6_Registry_8th_2008.pdf
10. CIMA: Centro de información online de medicamentos de la Agencia Española de Medicamentos y Productos Sanitarios. (Consultado 5 Septiembre 2011). Disponible en: http://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm&version=new
11. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251-60.
12. Major J, Reed MJ. A retrospective review of patients with head injury with coexistent anticoagulant and antiplatelet use admitted from a UK emergency department. Emerg Med J. 2009;26:871-6.
13. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991;28:3-5.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
15. Risk of Stroke with AF. VA Palo Alto Medical Center and at Stanford University: the Sports medicine Program and the Cardiomyopathy Clinic. (Consultado 5 Septiembre 2011). Disponible en: http://www.cardiology. org/tools/risk_of_stroke_AF.html. Retrieved 2007-09-14.
16. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost. 2010;104:45-8.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-72.
18. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
19. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest. 2010;18.
20. Lip GY, Frison L, Halperin JL, Lane DA. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation. The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score. J Am Coll Cardiol. 2011;57:173-80.
21. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9:1705-12.
22. Majeed A, Eelde A, Agren A, Schulman S, Holmström M. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res. 2012;129:146-51.
23. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313-20.
24. Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol. 2002;116:619-24.
25. Riess HB, Meier-Hellman A, Motsch J, Elías M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex(r) in patiens requiring immediate reversal of oral anticoagulation. Thrombosis Research. 2007;121:9-16.
26. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622-31.
27. Navarro JL, Cesar JM, Fernádez MA, Fontcuberta J, Reverter JC, Gol-Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol. 2007;60:1226-32.
28. Quintana Díaz M, Carvalho M. Libro electrónico de Medicina Intensiva, Sección 27: Hematologia. (Consultado 5 Septiembre 2011). Disponible en: http://intensivos.uninet.edu/27/2701.html
29. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251-60.
30. Major J, Reed MJ. A retrospective review of patients with head injury with coexistent anticoagulant and antiplatelet use admitted from a UK emergency department. Emerg Med J. 2009;26:871-6.
31. Lubestsky A, Hoffman R, Zimlichman R, Eldor A, Zus J, Kostenko V. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113:371-8.
32. Lesssinger C, Blatt P, Hoots W, Ewenstein B. Role of prothrobin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137-43.
33. Hay JW, Zhou ZY. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. J Med Econ. 2011;14:516-25.
34. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29:171-81.
35. Leal R, Alberca I, Asuero MS, Bóveda JL, Carpio N, Contreras E, et al. The Seville consensus document on alternatives to allogenic blood transfusion. Med Clin (Barc). 2006;127(Supl 1):3-20.